Core Viewpoint - The recent developments regarding the chairman of Beijing University Pharmaceutical (北大医药) indicate significant legal issues, with the chairman being arrested for criminal charges, yet the company's operations and control remain stable [1][2]. Group 1: Company Leadership and Governance - On November 12, Beijing University Pharmaceutical announced that its chairman and president, Xu Xiren, has been arrested for criminal charges, with the board functioning normally under the temporary leadership of authorized directors [1]. - Prior to the arrest, on October 25, the company had already announced Xu's temporary inability to perform his duties, delegating responsibilities to other board members [1]. - The company confirmed that its control structure has not changed and that its financial and operational management remains stable [2]. Group 2: Company Background and Operations - Beijing University Pharmaceutical, originally established in 1965, was listed on the Shenzhen Stock Exchange in 1997 and has undergone several changes in control, with the current actual controller being Xu Xiren [2][3]. - The company specializes in drug research, production, and sales, focusing on key areas such as anti-infection, analgesics, mental health, and chronic diseases, with a total of 166 drug approvals and 13 first-generic drug approvals [2]. - The company has developed a comprehensive pharmaceutical sales network across China, covering drug sales, medical circulation, hospital procurement, and supply chain management [2]. Group 3: Recent Performance Metrics - For the first three quarters of 2025, Beijing University Pharmaceutical reported a revenue of 1.231 billion yuan, a year-on-year decrease of 19.76%, while net profit increased by 4.31% to 136 million yuan [3].

Core Viewpoint - The chairman and president of Beijing University Pharmaceutical, Xu Xiren, has been criminally detained, affecting his ability to perform duties, while the company has appointed other executives to take over his responsibilities [1][4]. Group 1: Company Announcement - On October 25, the company announced that Xu Xiren temporarily could not perform his duties due to personal reasons and authorized Chen Yuezhong to act as chairman and Yu Mengchuan as president [4]. - The authorization is effective from the date of signing until Xu Xiren provides written notice to terminate it [4]. - The company has assured that its governance structure and internal control mechanisms are intact, and operations remain normal despite the leadership change [4]. Group 2: Company Background - Beijing University Pharmaceutical was established in 1965 and listed on the Shenzhen Stock Exchange in 1997 [5]. - The company became a member of the Ping An Group in 2022 and is controlled by Xu Xiren [5]. - The company focuses on drug research, production, and sales, with a portfolio of 166 drug approvals and 13 first-generic drug approvals [5]. Group 3: Financial Performance - In the first half of the year, the company reported total revenue of 957 million yuan, a decrease of 5.04% year-on-year, while net profit increased by 15.51% to 100 million yuan [6].

Group 1 - The stock price of Huahai Pharmaceutical closed at 22.72 yuan on July 30, down 1.43% from the previous trading day [1] - The stock reached a high of 24.24 yuan and a low of 22.55 yuan during the day, with a volatility of 7.33% [1] - The trading volume was 606,356 hands, with a total transaction amount of 1.406 billion yuan [1] Group 2 - Huahai Pharmaceutical operates in the chemical pharmaceutical industry, covering the research, production, and sales of active pharmaceutical ingredients and formulations [1] - The company is based in Zhejiang and its products are involved in cardiovascular, psychiatric, and antiviral fields [1] - During the early trading session on July 30, the stock experienced a rapid rebound, with price fluctuations exceeding 2% within five minutes [1] Group 3 - The main funds showed a slight net inflow on that day [1]